BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

Benzinga · 1d ago
BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.